1 Study Matches
A prospective, multi-national, non-interventional study in haemophilia A and B patients with or without inhibitors treated according to routine clinical treatment practice (explorer™6)
A non-interventional study designed to prospectively collect comprehensive data on bleeding episodes and health-related quality of life as well as on physical activity in patients with severe congenital haemophilia A (HA) and B (HB), with or without inhibitors under routine local clinical practice, irrespective of the treatment regimen.
Inclusion Criteria:age ≥ 12 years
Severe (< 1%) congenital hemophilia A or B with or without inhibitors
Pts with inhibitors treated on-demand: ≥ 6 treated (with bypassing agent) bleeding episodes within 24 wks of screening
Pts with severe congenital HA/HB treated on-demand: ≥ 5 treated (with factor product) bleeding episodes within 24 wks of screening
Pts with inhibitors treated with FEIBA prophylaxis: ≥ 2 treated bleeding episodes within 24 wks of screening
Exclusion Criteria:Known or suspected hypersensitivity to monoclonal antibodies
Previous treatment with concizumabdefined as two or more doses administered.
Planned FVIII/FIX Immune Tolerance Induction (ITI) regimens during the study.
Current or planned treatment with emicizumab.
Any known congenital or acquired coagulation disorder other than congenital hemophilia.